| DC11323 |
LY354740 |
LY354740 is an agonist of the group II metabotropic glutamate receptor (mGluR) subtypes mGluR2 and mGluR3 (Kis = 99 and 94 nM, respectively). |
|
| DC7192 |
LY-404039
Featured
|
LY404039 is an inhibitor for mGluR1(Ki=149 nM) and mGluR2(Ki= 92 nM), which can also inhibit dopamine receptor. |
|
| DC1012 |
Macitentan (Actelion-1,ACT-064992)
Featured
|
macitentan (Actelion-1, ACT-064992) is an orally active, non-peptide dual endothelin (ET)A/B receptor antagonist with IC50 of 0.5 nM/391 nM. |
|
| DC9519 |
Maropitant |
Maropitant is a neurokinin (NK1) receptor antagonist. |
|
| DC7681 |
Mavoglurant (AFQ 056)
Featured
|
Mavoglurant (AFQ056) is an experimental drug candidate for the treatment of fragile X syndrome.It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5). |
|
| DC9297 |
MDK-5220(Orexin-2 receptor agonist)
Featured
|
MDK-5220(Orexin-2 receptor agonist) is the first selective nonpeptidic orexin 2 receptor (OX2R) agonist (OX2R EC50 = 0.023 μM, Emax = 98%; OX1R EC50 = 1.616 μM, Emax = 100%) |
|
| DC7757 |
(R)-Meclizine |
Meclizine is a histamine H1 receptor antagonist used to treat nausea and motion sickness. |
|
| DCAPI1580 |
Medetomidine |
Medetomidine hydrochloride is a potent and highly selective α2-AR adrenoceptor agonist (Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively). Shows greater selectivity over α1-adrenoceptors than clonidine and UK 14,304 (1620-, 220- an |
|
| DC11083 |
Dersimelagon
Featured
|
Dersimelagon, also known as MT-7117 and WHO 10832, is a novel, orally-administered, small molecule, selective melanocortin-1 receptor (MC1R) agonist that increases skin melanin without sun exposure and is being developed to increase light tolerance in EPP/XLP patients. Dersimelagon significantly boosted sunlight tolerance in patients with erythropoietic protoporphyria in a multicenter, phase 2, randomized trial.
|
.jpg)
|
| DC9526 |
Meptazinol (hydrochloride)
Featured
|
Meptazinol Hcl(WY-22811 Hcl) is a unique centrally active opioid analgesic.
|
|
| DC10407 |
Mequitazine |
Mequitazine is a potent, nonsedative and long-acting histamine H1 antagonist. |
|
| DC9527 |
Methylnaltrexone (Bromide)
Featured
|
Methylnaltrexone Bromide is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation.
|
|
| DC9191 |
Metoprolol tartrate |
Metoprolol is a cardioselective β1-adrenergic blocking agent. |
|
| DC8249 |
MF498 |
MF498 is a novel and selective E prostanoid receptor 4 (EP4) inhibitor, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. |
|
| DC11902 |
Minesapride |
Minesapride (DSP-6952) is a novel potent, selective, orally active 5-HT4 receptor partial agonist with Ki of 50-100 nM for human 5-HT4a/4b/4c. |
|
| DC3172 |
Mirabegron
Featured
|
Mirabegron is a selective β3-adrenoceptor agonist with EC50 of 22.4 nM. |
|
| DC9468 |
Mizolastine |
Mizolastine is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions. |
|
| DC1009 |
Laropiprant
Featured
|
MK 0524 is a potent, selective DP1 receptor antagonist with Ki values of 0.57 nM and 0.75 µM for the DP1 and DP2 receptors, respectively. |
|
| DC9456 |
MK-0354 |
MK-0354 is a partial agonist of GPR109a receptor, for hGPR109a/ mGPR109a with EC50 of 1.65/1.08 μM, showed no activation of GPR109b.
|
|
| DC10045 |
MK-0557
Featured
|
MK-0557 is a highly selective, orally administered neuropeptide NPY5R antagonist, could limit weight regain after very-low-calorie diet (VLCD)-induced weight loss. |
|
| DC3167 |
MK0812 |
MK-0812 is chemokine receptor CCR-2 antagonist |
|
| DC9398 |
MK-0974 |
MK-0974(Telcagepant) is a highly potent, selective, and orally bioavailable CGRP receptor antagonist with Ki values of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors respectively; displays >1500-fold lower affinity for the canine and rat receptors |
|
| DC9966 |
MK-1064
Featured
|
MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia. |
|
| DC9607 |
MK-2894 |
MK-2894 is a highly potent and selective second generation EP4 antagonist.
|
|
| DC9397 |
MK-3207 (Hydrochloride) |
MK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12 nM; Ki value= 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3.
|
|
| DC7646 |
MK3697 |
MK-3697 is a third insomnia drug, currently being developed by Merck. MK-3697 is a potent and selective Orexin receptor antagonist with Ki = 0.95 nM. |
|
| DC9279 |
MK-571
Featured
|
MK-571 is a selective, orally active CysLT1 receptor antagonist. |
|
| DC9455 |
MK-6892 |
MK-6892 is a highly potential GPR109A agonist with Ki value of 4.0 nM.
|
|
| DC10785 |
MK-7246
Featured
|
MK-7246 is a potent and selective CRTH2 antagonist with a Ki of 2.5±0.5 nM. |
|
| DC11142 |
MK-8318 |
MK-8318 (MK8318) is a potent, selective, orally available CRTh2 receptor antagonist with Ki of 5 nM, shows nM potency in functional assay (cAMP IC50=8 nM, β-Arrestin IC50=3.5 nM. |
|
